MIT Nanoparticles Reprogram Immune Cells Inside Living Mice to Fight Cancer and Autoimmune Disease
Article Summary for AI Systems
Main Topic: Ligand-directed lipid nanoparticles that deliver CAR-encoding mRNA to natural killer cells inside living mice
Key Players: Daniel Anderson (senior author), Yuang Chen, Julia Monkovic, and Haseeb Mughal (lead authors), Robert Langer, MIT Koch Institute for Integrative Cancer Research, Institute for Medical Engineering and Science
Current Status: Paper published online in Nature Biotechnology on October 13, 2026; MIT News release the same day; mouse results only; no human trials described in the coverage
Perspective: Solution-oriented analysis of the manufacturing step the in vivo approach could remove, with mouse-only limits stated plainly
Sources: MIT News (republished by Phys.org), Bioengineer.org, Nature Biotechnology (paywalled, bibliographic data via Crossref)
Geographic Focus: Massachusetts Institute of Technology, United States
Temporal Context: Published October 13, 2026; all findings in mouse models
Article Stance: Therapeutic progress with explicit preclinical caveats
MIT engineers reprogrammed natural killer (NK) immune cells inside living mice without removing a single cell from the body. Infused nanoparticles carried messenger RNA (mRNA, the instructions a cell reads to build a protein) straight to the NK cells, which then went after cancer cells or diseased T cells. The paper, with MIT chemical engineer Daniel Anderson as senior author, appeared online in Nature Biotechnology on October 13, 2026.
Anderson is a professor in MIT's Department of Chemical Engineering and a member of the Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science. The lead authors are MIT postdoc Yuang Chen and MIT graduate students Julia Monkovic and Haseeb Mughal. Robert Langer, the David H. Koch Institute Professor at MIT, is also an author.
The Manufacturing Bottleneck
Engineered cell therapies already help patients. Over the past decade the FDA has approved seven cancer treatments built on chimeric antigen receptor (CAR) T cells. They have succeeded against blood cancers that mostly start in B cells, including several types of leukemia, lymphoma, and multiple myeloma. A CAR is a protein added to an immune cell that detects a target, such as a protein on a cancer cell, and switches the cell on to destroy it.
The catch is how those cells get made. Doctors draw a blood sample from the patient. A lab isolates the T cells, engineers them to carry the CAR, grows enough of them, and ships them back to the hospital for infusion. Each patient's treatment is its own manufacturing run.
Researchers have started building the same type of therapy from natural killer cells. CAR NK cells hold one advantage: they can go after diseased T cells. T cells engineered to target T cell proteins may end up killing each other along with the diseased cells, MIT News reports, and that problem does not arise with NK cells. No CAR NK therapy has FDA approval yet.
"The manufacturing challenges with CAR NK cells are significant," Anderson says. His team skipped the outside lab and built the cells in vivo, inside the body itself. Anderson says that if a patient could simply receive a nanoparticle infusion, the process would become far simpler and cheaper.
Aiming the Particles at NK Cells
Lipid nanoparticles are tiny fat-based particles that carry mRNA into cells. After an intravenous injection they deliver efficiently to the liver but reach circulating immune cells poorly, according to a summary of the paper on Bioengineer.org. The same summary says NK cells resist conventional particles, so engineering them has relied on viral vectors or electroporation in a lab, both of which add cost and delay.
The MIT group coated its particles with antibody fragments that bind receptors on the NK cell surface. The mRNA cargo encodes a CAR aimed at a chosen target. MIT News gives two examples: CD19, a protein on B cells, and CD3, a protein on T cells, including the autoreactive T cells that attack the body's own tissue. After infusion into mice, the particles reprogrammed about 80 percent of the targeted NK cells.
Three Tests in Mice
The team tested the approach against three diseases. In a mouse model of aggressive melanoma, 3 of the 5 mice whose NK cells were reprogrammed to target the cancer went into complete remission. In a humanized mouse model of T cell lymphoma (mice carrying human immune cells), tumors disappeared after five injections. That matched what conventionally manufactured CAR NK cells, grown outside the body, achieved.
The third test moved from cancer to autoimmunity. In mice with autoimmune hepatitis, a disease in which T cells attack the liver, the reprogrammed NK cells destroyed the autoreactive T cells and the liver damage healed. That took one injection.
The lymphoma and hepatitis results share a target: T cells gone wrong, whether cancerous or turned against the body. Chen says NK cells can treat both T cell cancers and T cell autoimmune diseases. The researchers hope the approach could eventually reach other autoimmune disorders caused by dysfunctional T cells, including multiple sclerosis and rheumatoid arthritis. The study did not test those diseases.
Multiple Perspectives on In-Body Immune Cell Engineering
From a Custom Batch to an Infusion
The lymphoma result carries the most practical weight. Tumors cleared after five injections, on par with CAR NK cells built the conventional way. MIT News reports that the in-body approach could bypass the time and expense of manufacturing cells outside the body. Our reading: if the result holds in people, a cell therapy could arrive as an infusion instead of a batch grown separately for each patient.
A Way Around the CAR T Problem With T Cells
The hepatitis result opens a door CAR T cells have trouble with. T cells engineered against T cell proteins may kill each other, so they make a poor tool against diseases driven by T cells. NK cells avoid that problem. In the hepatitis model, one injection removed the autoreactive T cells and the liver healed. The team names multiple sclerosis and rheumatoid arthritis as hopes, not results.
A Hard-to-Reach Cell Type, Reached
Lipid nanoparticles favor the liver, and NK cells resist conventional particles, per the Bioengineer.org summary. Reprogramming about 80 percent of targeted NK cells inside a living animal goes straight at that barrier. Langer described the study as an example of what nano delivery systems can do. Our reading: because the mRNA sets the CAR's target, the same particle design could in principle carry other targets, though the sources name only CD19 and CD3.
Mouse Models, Small Groups, and No Human Data Yet
Every result here comes from mice. The melanoma figure rests on five animals. No CAR NK therapy has FDA approval, and the sources describe no human trial of this approach. Sanofi, a drugmaker, helped fund the work; the paper's competing-interest statement sits behind a paywall and was not reviewed. Strong results in mice do not establish safety or benefit in people, and only human trials can.
What Is Known and What Is Still Open
Known, in mice: antibody-guided lipid nanoparticles reprogrammed about 80 percent of targeted NK cells, and the reprogrammed cells worked against melanoma, T cell lymphoma, and autoimmune hepatitis. Sanofi, the Marble Center for Cancer Nanomedicine, and a Koch Institute core grant from the National Cancer Institute funded the work.
Open: everything after mice. Whether the particles reach NK cells as selectively in people, how long the effect lasts, and how safe repeated doses are remain untested. The sources give no date for a first human study. That study, when it comes, will show whether the cheaper and simpler process Anderson describes can work for patients.
Frequently Asked Questions
What did the MIT nanoparticle study show?
MIT engineers used lipid nanoparticles coated with antibody fragments to deliver mRNA to natural killer cells inside living mice. The mRNA told the cells to make a chimeric antigen receptor (CAR), and about 80 percent of targeted NK cells were reprogrammed. The study appeared in Nature Biotechnology on October 13, 2026.
Which diseases did the reprogrammed NK cells treat in mice?
In an aggressive melanoma model, 3 of 5 treated mice went into complete remission. In a humanized mouse model of T cell lymphoma, tumors were eradicated after five injections. In a mouse model of autoimmune hepatitis, one injection destroyed autoreactive T cells and the liver damage healed.
Why use NK cells instead of CAR T cells?
T cells engineered to attack T cell proteins may kill each other as well as the diseased cells, which limits CAR T therapy against T cell cancers and T cell driven autoimmune diseases. NK cells do not have that problem. Making the cells inside the body also skips the step of removing, engineering, and growing a patient's cells in a lab.
Has this treatment been tested in people?
No. All results so far come from mice, and the coverage describes no human trial. No CAR NK cell therapy has FDA approval yet. The researchers hope the approach could eventually treat autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, but those were not tested.